Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash & Equivalents (2018 - 2019)

DiaMedica Therapeutics' Cash & Equivalents history spans 2 years, with the latest figure at $4.7 million for Q3 2019.

  • For Q3 2019, Cash & Equivalents rose 21.63% year-over-year to $4.7 million; the TTM value through Sep 2019 reached $4.7 million, up 21.63%, while the annual FY2018 figure was $16.8 million, N/A changed from the prior year.
  • Cash & Equivalents reached $4.7 million in Q3 2019 per DMAC's latest filing, up from $3.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $16.8 million in Q4 2018 to a low of $2.8 million in Q1 2019.